About
Miroslav Gasparek is CEO and co-founder of Sensible Biotechnologies, a cell-based mRNA production platform. He studied bioengineering at Imperial College London and engineering at Oxford, and has worked on Slovak biosecurity policy development.
Miroslav Gasparek @mirogasparek
Europe’s medicines supply chain is not a theoretical policy problem. It is being hollowed out in real time. The Financial Times reports that Xellia Pharmaceuticals, Europe’s last manufacturer of ingredients for some vital antibiotics, is closing its biggest domestic factory in
Jul 1, 2026 · ♥ 1 · ⇄ 1
Miroslav Gasparek @mirogasparek
Meeting @kkariko at Oxford was deeply meaningful. Her Nobel-winning work helped make mRNA medicines possible. For a Slovak engineer building novel mRNA tech @sensible_bio, meeting a Hungarian scientist who changed medicine was powerful: Central Europe can shape the future too. https://t.co/jERReaZ67B
Jun 25, 2026 · ♥ 6 · ⇄ 1
Miroslav Gasparek @mirogasparek
Europe’s BioShield won’t be built by policy alone. It will require robust mRNA supply chains, local manufacturing, scale-up and public-private execution. @sensible_bio aims to play leading role in this. Great discussion at bio:cap 2026 in Berlin. Thanks @handelsblatt for invite! https://t.co/0EoknXQQBZ
Jun 24, 2026 · ♥ 4 · ⇄ 1
Founder at Sensible BiotechnologiesYC S21
Intro paths
Miroslav went through Y Combinator (Summer 2021) — any YC alum in your network can reach them through the YC community.
Their group partner at YC was Jared Friedman, General Partner at Y Combinator — the partner who ran Sensible Biotechnologies's batch and knows the company first-hand. YC profile ↗
In turn, Miroslav can intro founders to Sensible Biotechnologies's investors below.
Sensible Biotechnologies's investors · 6
Co-founders at Sensible Biotechnologies
